Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLCs registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Storz

Executive Summary

American Cyanamid subsidiary receives April 11 reg letter on promotion of Ocuvite, a zinc supplement for eyes. FDA said the company has been promoting the vitamin and mineral product as a prevention or treatment for such conditions as senile macular degeneration, cataracts, night blindness, severe near-sightedness and injuries to the cornea, which constitute drug claims. Storz said that it would meet with FDA at the beginning of the week of May 7 to discuss the agency's objections. In the meantime, the company has stopped all promotion, including journal ads and mailings, for the product, which is manufactured by Lederle. Storz said that Ocuvite promotions target ophthalmologists to encourage them to recommend the product as a preferred zinc supplement to their patients, and that FDA objections probably were directed at a brochure being distributed that specifically mentioned certain eye conditions.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS017401

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel